NCT05028114 is a Phase 1 clinical trial of AC-1202 in Alzheimer Disease, sponsored by Cerecin.

Who is sponsoring NCT05028114?

NCT05028114 is sponsored by Cerecin.

What drugs are being tested in NCT05028114?

Interventions in NCT05028114: AC-1202, AC-OLE-01, AC-OLE-02, AC-OLE-03, AC-OLE-04, AC-OLE-05, AC-OLE-06, AC-OLE-07, AC-OLE-08, AC-OLE-09, AC-OLE-010, AC-OLE-P.

What condition does NCT05028114 study?

NCT05028114 studies Alzheimer Disease.

Is NCT05028114 still recruiting?

NCT05028114 is currently terminated. Last updated 17 October 2023.

Last reviewed 2023-10-17 · How we verify

NCT05028114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tricaprilin Liquid Formulation PK Study

Terminated Phase 1 Last updated 17 October 2023

What this trial tests

Phase 1 trial testing AC-1202 in Alzheimer Disease in 71 participants. Terminated before completion.

Timeline

31 August 2021

Primary endpoint
18 March 2022

19 July 2022

Quick facts

Lead sponsor	Cerecin
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	71
Start date	31 August 2021
Primary completion	18 March 2022
Estimated completion	19 July 2022
Sites	1 location across Australia

Drugs / interventions tested

AC-1202 — full drug profile →
AC-OLE-01
AC-OLE-02 — full drug profile →
AC-OLE-03
AC-OLE-04
AC-OLE-05
AC-OLE-06 — full drug profile →
AC-OLE-07
AC-OLE-08 — full drug profile →
AC-OLE-09 — full drug profile →
AC-OLE-010
AC-OLE-P

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Cerecin — full company profile →

Who can join

Adults 18 to 65, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of new liquid formulations of tricaprilin, with the aim of finding a suitable formulation to advance in development. This is a three-part, part-randomised study that include single-dose, food effect, and titration tolerability in up to 80 healthy participants.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2022.
Cummings J, Lee G, Nahed P, Kambar MEZN, et al · · 2022 · cited 369× · PMID 35516416 · DOI 10.1002/trc2.12295
Alzheimer's disease drug development pipeline: 2023.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2023 · cited 326× · PMID 37251912 · DOI 10.1002/trc2.12385

Verify or expand the search:

Other trials of AC-1202

Trials testing the same drug.

NCT03635879 — Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides · Phase 1 · withdrawn
NCT03063645 — Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production · Phase 1 · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Cerecin trials

Trials by the same sponsor.

NCT05628636 — AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions · Phase 1 · completed
NCT05408780 — A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation · Phase 1 · completed
NCT04187547 — A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Diseas · Phase 3 · withdrawn
NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
NCT04437199 — Tricaprilin Phase 2 Pilot Study in Migraine · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05028114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cerecin
Last refreshed: 17 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05028114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing